Stock 4130 GENOVATE BIOTECHNOLOGY CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Genovate Biotechnology Co., Ltd.

Equities

4130

TW0004130000

Pharmaceuticals

End-of-day quote Taipei Exchange
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
24.45 TWD +0.41% Intraday chart for Genovate Biotechnology Co., Ltd. +2.30% -8.08%
Mar. 28 Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 2,840 2,634 3,152 2,675 3,506 2,909
Enterprise Value (EV) 1 2,368 2,177 2,733 2,287 3,011 2,371
P/E ratio 49.1 x 78.3 x 81.4 x 8,267 x -285 x 99.2 x
Yield 1.06% 1.86% 1.38% 1.41% 0.54% 0.56%
Capitalization / Revenue 6.23 x 5.66 x 6.67 x 6.16 x 7.99 x 5.5 x
EV / Revenue 5.2 x 4.67 x 5.78 x 5.27 x 6.86 x 4.49 x
EV / EBITDA 37.5 x 30.5 x 37.8 x 70.7 x 151 x 38.9 x
EV / FCF -199 x 195 x 81.4 x -97 x -816 x 40.3 x
FCF Yield -0.5% 0.51% 1.23% -1.03% -0.12% 2.48%
Price to Book 1.82 x 1.86 x 2.21 x 1.94 x 2.52 x 1.98 x
Nbr of stocks (in thousands) 109,436 109,404 107,876 107,876 107,876 109,376
Reference price 2 25.95 24.08 29.22 24.80 32.50 26.60
Announcement Date 3/28/19 3/30/20 3/26/21 3/29/22 3/25/23 3/28/24
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 455.8 465.8 472.7 434.3 438.8 528.5
EBITDA 1 63.08 71.49 72.32 32.33 19.94 60.9
EBIT 1 31.59 39.48 39.5 -1.166 -13.89 27.01
Operating Margin 6.93% 8.48% 8.36% -0.27% -3.17% 5.11%
Earnings before Tax (EBT) 1 63.94 40.67 40.76 3.568 -9.001 30.82
Net income 1 57.85 34.06 38.73 0.372 -12.32 29.33
Net margin 12.69% 7.31% 8.19% 0.09% -2.81% 5.55%
EPS 2 0.5286 0.3076 0.3590 0.003000 -0.1142 0.2682
Free Cash Flow 1 -11.88 11.18 33.59 -23.57 -3.688 58.76
FCF margin -2.61% 2.4% 7.11% -5.43% -0.84% 11.12%
FCF Conversion (EBITDA) - 15.64% 46.44% - - 96.47%
FCF Conversion (Net income) - 32.84% 86.72% - - 200.3%
Dividend per Share 2 0.2746 0.4469 0.4020 0.3500 0.1750 0.1500
Announcement Date 3/28/19 3/30/20 3/26/21 3/29/22 3/25/23 3/28/24
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 472 457 419 389 495 539
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -11.9 11.2 33.6 -23.6 -3.69 58.8
ROE (net income / shareholders' equity) 3.66% 2.29% 2.73% 0.03% -0.88% 2.04%
ROA (Net income/ Total Assets) 1.05% 1.49% 1.57% -0.05% -0.56% 1.07%
Assets 1 5,535 2,283 2,466 -788.1 2,186 2,750
Book Value Per Share 2 14.30 12.90 13.20 12.80 12.90 13.40
Cash Flow per Share 2 2.010 1.840 2.070 1.840 1.780 1.650
Capex 1 35.3 25.8 27 18 23.5 28
Capex / Sales 7.74% 5.53% 5.71% 4.14% 5.37% 5.29%
Announcement Date 3/28/19 3/30/20 3/26/21 3/29/22 3/25/23 3/28/24
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
GENOVATE BIOTECHNOLOGY CO., LTD. Stock Genovate Biotechnology Co., Ltd.
-8.08% 82M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+33.25% 704B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+28.59% 577B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.55% 348B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.16% 327B
ABBVIE INC. Stock AbbVie Inc.
+4.36% 288B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.81% 234B
NOVARTIS AG Stock Novartis AG
+4.93% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-9.78% 194B
AMGEN INC. Stock Amgen Inc.
-3.69% 147B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 4130 Stock
  4. Financials Genovate Biotechnology Co., Ltd.